Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 02 2025
0mins
Source: Globenewswire
First Patient Enrolled: Integra LifeSciences has enrolled the first patient in the Acclarent AERA Pediatric Registry, which aims to evaluate the real-world use of the AERA Eustachian Tube Balloon Dilation System in children with obstructive Eustachian tube dysfunction.
Registry Objectives: The registry will assess safety and efficacy outcomes for up to 300 pediatric patients, focusing on failure-free status post-procedure and capturing various clinical data to enhance understanding and treatment of pediatric Eustachian tube dysfunction.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
